Phase II trial of serplulimab combined with gemcitabine plus nab-paclitaxel (GnP) and SBRT for metastatic pancreatic cancer as the first-line treatment.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ke Cheng, Chenyan Zhang, Gang Zhao, Xiaoying Li, Jiaxin Liu, Zhiping Li, Heqi Yang, Bole Tian, Chengjian Zhao, Dan Cao
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410815233